A recent study completed at Roswell Park Cancer Institute is helping redefine how we use the PSA (prostatespecific antigen) test for prostate cancer patients by demonstrating that even when PSA is present, the levels of the marker can be a key indicator of what treatment is necessary—or unnecessary.
Read more: http://goo.gl/kkPLfW